儿科药学杂志2025，Vol.31Issue(2)：1-5,5.DOI:10.13407/j.cnki.jpp.1672-108X.2025.02.001
基于加权逼近理想解排序法的急性淋巴细胞白血病患儿大剂量甲氨蝶呤药物利用评价及典型案例分析
Drug Utilization Evaluation and Typical Case Analysis of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia Based on Weighted Technique for Order Preference by Similarity to Ideal Solution Method
摘要
Abstract
Objective:To establish the drug utilization evaluation(DUE)and typical case analysis of high-dose methotrexate(HDMTX)in children with acute lymphoblastic leukemia(ALL)based on weighted technique for order preference by similarity to ideal solution(TOPSIS)method,so as to promote the clinical rational application.Methods:Based on drug instructions of methotrexate(MTX)and by referring to relevant clinical guidelines and literature on the clinical application of HDMTX,DUE criterion for HDMTX in ALL children based on the weighted TOPSIS method was established.The application of HDMTX in our hospital from 2021 to 2023 was retrospectively evaluated according to the DUE criteria.Results:According to the weighted TOPSIS method evaluation of 150 medical records,the weighted Euclid distance(Ci)was ≤60％in 15 cases(10％),from 60％to 70％in 51 cases(34.00％),＞70％to 80％in 73 cases(48.67％),and ≥80％in 11 cases(7.33％).Conclusion:The evaluation criteria of HDMTX in children with ALL based on weighted TOPSIS method can be used to evaluate the application rationality in children.The evaluation results show that there are irrational clinical application of HDMTX in our hospital,and it is necessary to further strengthen the control and multidisciplinary cooperation,and promote the rational medication.关键词
急性淋巴细胞白血病/儿童/加权逼近理想解排序法/大剂量甲氨蝶呤/药物利用评价Key words
acute lymphocyte leukemia/children/weighted technique for order preference by similarity to ideal solution method/high-dose methotrexate/drug utilization evaluation分类
医药卫生引用本文复制引用
孙丽,许锦,赵兴辉,吴庆涛,韩兆欢,安琪,刘育青,王磊..基于加权逼近理想解排序法的急性淋巴细胞白血病患儿大剂量甲氨蝶呤药物利用评价及典型案例分析[J].儿科药学杂志,2025,31(2):1-5,5.基金项目
徐州市卫生健康委员会药学科研项目,编号XWYXKY202303 （）
江苏省药学会-奥赛康医院药学科研项目,编号A202339 （）
徐州医科大学附属徐州市儿童医院科研项目,编号23040419. （）
